Author:
Strand Niels August Willer,Nielsen Mette Ødegaard,Nielsen Jimmi
Abstract
Long-acting injectable antipsychotics (LAI) is a frequently used treatment modality which has advantages over oral antipsychotics regarding hospitalization or relapse prevention. However, the pharmacokinetic properties of LAI greatly differ from oral antipsychotics. This necessitates an increased knowledge about LAI among clinicians, especially when commencing treatment, changing doses and discontinuing treatment. In this review, we summarize an array of clinically important characteristics of LAI and give a conceptual framework for understanding the pharmacokinetics of LAI.
Publisher
Danish Medical Association
Reference29 articles.
1. Higashi K, Medic G, Littlewood KJ et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200-18. doi: 10.1177/2045125312474019.
2. Alvarez-Jimenez M, Priede A, Hetrick SE et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1-3):116-28. doi: 10.1016/j.schres.2012.05.007.
3. Kishimoto T, Hagi K, Kurokawa S et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi: 10.1016/S2215-0366(21)00039-0.
4. Fink-Jensen A. Depotpræparater (antipsykotika). Pro.medicin.dk, 2023. https://pro.medicin.dk/Laegemiddelgrupper/Grupper/237050 (26. okt 2023).
5. Medicinrådet. Baggrund for Medicinrådets behandlingsvejledning vedrørende antipsykotika til behandling af psykotiske tilstande hos voksne. https://medicinraadet.dk/media/41dd10ko/baggrund-for-medicinr%C3%A5dets-behandlingsvejledning-vedr-antipsykotika-til-voksne-vers-1-0-adlegacy.pdf (25. okt 2023).